🟢 OCGN is trading 5% up today following participation in June investor and industry conferences

OCGN is trading about 5% up at $1.45.

• The upward move follows Ocugen's active participation in investor and industry conferences throughout June 2026, including a presentation on its innovative gene therapy platform at the BIO International Convention on June 23, 2026.
• The company has been highlighting advancements in its gene therapy programs for blindness diseases, with key catalysts expected in 2026 and 2027 for its ocular pipeline.
• There are no fresh earnings, FDA decisions, or major deals specifically reported for June 24, 2026.